Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07749716
PHASE2

Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata

Sponsor: Jiangsu vcare pharmaceutical technology co., LTD

View on ClinicalTrials.gov

Summary

This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study designed to evaluate the efficacy and safety of VC005 tablets in subjects with severe alopecia areata (AA).

Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Severe Alopecia Areata

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2026-08-18

Completion Date

2028-12-30

Last Updated

2026-08-27

Healthy Volunteers

No

Conditions

Interventions

DRUG

Drug: VC005 tablets

VC005 repeat administration for 24 weeks

DRUG

VC005 tablets

VC005 repeat administration for 24 weeks

DRUG

VC005 placebo tablets

VC005 placebo repeat administration for 24 weeks

Locations (1)

The Peking University People's Hospital, Beijing, Beijng

Beijing, Beijing Municipality, China